Market Overview

Navidea Biopharma Says PDUFA Goal Date for Lymphoseek April 30, 2013

Share:
Related NAVB
Macrophage Therapeutics Reports Data Demonstrating a Manocept™ Drug Conjugate Induces Apoptosis in CD206 Positive Kaposi's Sarcoma and Tumor Associated Macrophages
Navidea Announces Clinical Data for Manocept Shows Agent Localizes in Multiple KS Lesions
Premarket Biotech Digest: Amgen Beats, GlaxoSmithKline Corruption Charges, VTv Therapeutics Flops On Debut (Seeking Alpha)

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the Company's October 30, 2012 resubmission of its New Drug Application (NDA) for Lymphoseek (Technetium Tc 99m Tilmanocept) Injection. In its acknowledgment, FDA noted that it considers the filing a complete, class 2 response to its September 10, 2012 action letter and has set a Prescription Drug User Fee Act (PDUFA) goal date of April 30, 2013. Lymphoseek ^ is a novel, receptor-targeted, small-molecule, investigational radiopharmaceutical used in lymphatic mapping procedures that are performed to help stage cancer. Lymphoseek is designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer.

Posted-In: News FDA

 

Related Articles (NAVB)

Get Benzinga's Newsletters